Trustworthy of CA 15-3 in the follow up of patients with breast cancer and bone metastases;Confiabilidad del CA 15-3 como seguimiento en las pacientes con carcinoma mamario y metástasis óseas

Revista de Investigacion Clinica

Volumn 55, Issue 4, 2003, Pages 412-418

  Estrada Sánchez, Gisela del Rocío ^a   Enríquez, Martha Mireles ^a   Castañeda, Norma Valverde ^a  

^a CENTRO MÉDICO NACIONAL 20 DE NOVIEMBRE   (Mexico)

Author keywords

Bone metastases; Bone scintigraphy; Breast cancer; CA 15 3; Tc99m MDP

Indexed keywords

ANTINEOPLASTIC AGENT; CA 15-3 ANTIGEN; MEDRONATE TECHNETIUM TC 99M; TAMOXIFEN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER STAGING; CONCENTRATION (PARAMETERS); DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL RECORD; QUANTITATIVE ANALYSIS; RADIOIMMUNOASSAY; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BREAST NEOPLASMS; CA-15-3 ANTIGEN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 0344466683     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Colomer R, Sole LA, Navarro M, et at. CA 15-3 early results of a new breast cancer marker. Anticancer Res 1986; 6: 683-4.
2. Safi F, Kohler I, Rottinger E, et al. The value of the tumour marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Cancer 1991; 68: 574-82.
3. Friedmann E, Hayes D, Kufe D. Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas. Cancer Res 1986; 46: 5189-94.
4. Colomer R, Ruibal A, Salvador L. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastasic disease. Cancer 1989; 64(8): 1674-81.
5. Jilkensd J, Kroezen V, Bonfrer JM, et al. MAM-6 antigen: A new serum marker for breast cancer monitoring. Cancer Res 1986; 46: 2582-7.
6. Tobias R, Rothwell C, Wagner J, et al. Development and evaluation of a radioimmunoassay for the detection or a monoclonal antibody defined breast cancer associated antigen 115D8/DF3. Chemistry 1985; 1: 73-4.
7. Gion M, Mione R, Nascimben O, et al. The tumour associated antigen CA 15-3 in primary breast cancer. Br J Cancer 1991; 63: 809-13.
8. O'Brien D, Mc Glone, Younis, et al. Baseline isotope bone scintigraphy in women with mammary carcinoma: Is it necessary? Breast Dis 1993; 6: 113-18.
9. Horobin J, Browning M, McFarlane N, et al. Potential use of tumor marker CA 15-3 in the staging and prognosis of patients with breast cancer. JR Coll Surg Edinb 1991; 04(36): 219-303.
10. Fernandez-Ulloa M, Klostermaier T, Lancaster K. Orthopaedic Nuclear Medicine: The pelvis and hip. Semin Nucl Med 1998; 38(1): 25-40.
11. O'Brien D, Horgan P, Gough D. Ca 15-3: A reliable indicator or metastatic bone disease in breast cancer patients. Ann Roy Coll Surg Engl 1992; 74: 9-12.
12. Sánchez Basurto C. Compendio de patología mamaria. 1a. Ed. Ed. G. JGH editores; 1999, p. 21-341.
13. Brown LM. Bone scientigraphy in bening and malignant tumors. Radiol Clin N Am 1993; 31(4): 731-8.
14. Brown L, Collier B, Fogelman B. Vone scintigraphy: Oncology and infection. J Nucl Med 1993; 34: 2236-40.
15. Krasnow A, Hellman R, Timis M, et al. diagnostic bone scanning in oncology. Semin Nucl Med 1997; 27(2): 107-41.
16. Tryciecky E, Gottschalk A, Ludema K. Oncologic imaging: Interactions of nuclear medicine with CT and MRI using the bone scan as a model. Semin Nucl Med 1997; 27(2): 142-51.
17. Ackerman. Surgical pathology. octava edición. Ed Mosby; 1996, p. 1590-626.
18. Mc Ewan A. Unsealed source therapy of painful bone metastases: An update. Semin Nucl Med 1997; 27(2): 165-82.
19. Gosfield A, Alavi N, Kneeland K. Comparison of radionuclide bone scans and magnetic resonance imagin in detecting spinal metastasis. J Nucl Med 1992; 33: 1801-9.
20. Kerin M, Mc Anene O, O'Malley V, et al. CA 15-3: its relationship to clinical stage and progression to metastasic disease in breast cancer. Br J Surg 1989; 76: 838-9.
21. Robertson J, Pearson D, Price M, et al. Assessment of four monoclonal antibodies as serum markers in breast cancer. Eur J Cancer 1990; 26(1): 1127-32.
22. O'Dwyer P, Duffy M, O'Sullivan F. CEA and CA 15-3 in primary and recurrent breast cancer. World J Surg 1990; 14: 562-6.
23. Saenz RB, Phillips DM. Cancer and metastatic disease. Prim Care 1998; 25(2): 309-21.
24. Jacobson A, Stomper P, Jochelson M, et al. Association between number and sites of new bone scan abnormalities and presence of skeletal metastases in patients with breast cancer. J Nucl Med 1990; 31: 387-92.
25. Jacobson A, Shapiro C, Van den Abbeele A, et al. Prognostic significance of number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma. Cancer 2001; 91: 17-24.
26. Briasoulis E, Andreopoulou E, Tolis C, et al. G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting. Cancer 2001; 91: 909-17.
27. Younsi N, Montravers F, Phillippe C, et al. CA 15-3 and bone scintigraphy in the follow up of cancer. Int J Biol Markers 1997; 12(4): 154-7.
28. Lauro S. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow up and monitoring therapeutic response in cancer patients. Anticancer Res 1999; 19(4c): 3511-15.
29. Bast R, Allen S, Desch C, et al. Clinical practice guidelines for the use of tumor markers in cancer. J Clin Oncol 1996; 14(10): 2843-77.